AR and pachyonychia congenita: Our lab also reported that the NEPC driver gene, SRRM4, is expressed in 16% of hormone-naïve primary tumours, and SRRM4-positive tumour cells increased to ~30% of tumours under AR target therapy, supporting the idea that CRPC tumour cells are pre-composite in untreated PC and become prevalent upon anticancer treatment [13].